Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In 2014, the American Diabetes Association instituted a novel funding paradigm to support diabetes research through its Pathway to Stop Diabetes program. This program took a multifaceted approach to providing key funding to diabetes researchers to advance a broad spectrum of research programs on all aspects of understanding, managing, and treating diabetes. Here, the personal perspective of a 2019 Pathway Accelerator awardee is offered, describing a research program seeking to advance a materials-centered approach to engineering glucose-responsive devices and new delivery tools for better therapeutic outcomes in treating diabetes. This is offered alongside a personal reflection on 5 years of support from the ADA Pathway Program.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2337/dbi23-0029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spiritual interventions, including meditation, prayer, mindfulness, and compassionate care, have gained increasing attention for their potential to enhance both psychological resilience and overall health. This systematic review and meta-analysis examined eight eligible studies conducted across the USA, Europe, and China to assess the impact of such interventions on key outcomes, namely anxiety reduction, quality of life, chronic disease symptom management, and patient satisfaction. Seven studies contributed quantitative data.
View Article and Find Full Text PDFManaging diabetes in older adults requires balancing long-term glycaemic control with the prevention of hypoglycaemia, to which this population is particularly vulnerable owing to frailty, multimorbidity and cognitive decline. Guidelines recommend individualized glucose targets for older adults, particularly those with multimorbidity or increased hypoglycaemia risk. For individuals with frailty or cognitive impairment, relaxed HbA1c targets are often appropriate to reduce the risk of adverse events.
View Article and Find Full Text PDFUnraveling the Systems Biology of Curcumin: A Mini-review of its Anti-diabetic Potential through Network Pharmacology.
Cell Biochem Biophys
September 2025
Faculty of Industrial Sciences and Technology, Universiti Malaysia Pahang Al-Sultan Abdullah, Lebuhraya Persiaran Tun Khalil Yaakob, Gambang, Kuantan, Pahang, Malaysia.
[Sex differences in the pharmacological treatment of hypertension in primary care].
Ned Tijdschr Geneeskd
September 2025
UMC Utrecht, afd. huisartsgeneeskunde, Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde, Utrecht.
Objective: To investigate sex differences in the pharmacological treatment of hypertension in primary care.
Design: Cross-sectional study among 14,384 patients with hypertension from the Julius General Practitioners' Network, without cardiovascular disease or diabetes, treated with antihypertensive medications.
Methods: We compared men and women in the number and type of prescribed antihypertensives and their blood pressure.
[Therapeutic advances in metabolic dysfunction-associated steatotic liver disease].
Rev Med Suisse
August 2025
Service de gastroentérologie et d'hépatologie, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.
The treatment of metabolic dysfunction-associated steatotic liver disease involves physical activity, weight loss, and management of comorbidities (diabetes, hypertension, dyslipidemia). In 2024, the American Food and Drug Administration provisionally approved resmetirom for metabolic dysfunction-associated steatohepatitis. Other promising molecules are being evaluated (glucagon-like peptide 1 receptor agonists, fibroblast growth factor 21 agonist).
View Article and Find Full Text PDF